Literature DB >> 15148229

Photodynamic therapy for corneal neovascularisation and lipid degeneration.

B J Brooks, B K Ambati, D M Marcus, A Ratanasit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15148229      PMCID： PMC1772199          DOI： 10.1136/bjo.2003.035071

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  4 in total

1.  Photodynamic therapy for corneal neovascularization using topically administered ATX-S10 (Na).

Authors:  Y Gohto; A Obana; M Kanai; S Nagata; T Miki; S Nakajima
Journal:  Ophthalmic Surg Lasers       Date:  2000 Jan-Feb

2.  Treatment parameters for selective occlusion of experimental corneal neovascularization by photodynamic therapy using a water soluble photosensitizer, ATX-S10(Na).

Authors:  Y Gohto; A Obana; M Kanai; S Nagata; S Nakajima; T Miki
Journal:  Exp Eye Res       Date:  2001-01       Impact factor: 3.467

3.  Photodynamic therapy for corneal neovascularization.

Authors:  G B Primbs; R Casey; K Wamser; W J Snyder; D H Crean
Journal:  Ophthalmic Surg Lasers       Date:  1998-10

4.  Photodynamic therapy of corneal neovascularization with verteporfin.

Authors:  Maurizio Fossarello; Enrico Peiretti; Ignazio Zucca; Antonina Serra
Journal:  Cornea       Date:  2003-07       Impact factor: 2.651
  4 in total
  10 in total

1.  Suppression of corneal neovascularization by curcumin via inhibition of Wnt/β-catenin pathway activation.

Authors:  Yong-Kang Zhang; Jing-Ming Li; Li Qin
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

Review 2.  Horizons in therapy for corneal angiogenesis.

Authors:  Surekha Maddula; Don K Davis; Soumya Maddula; Michael K Burrow; Balamurali K Ambati
Journal:  Ophthalmology       Date:  2011-03       Impact factor: 12.079

3.  Bilateral severe progressive idiopathic lipid keratopathy.

Authors:  Jaime Levy; Daniel Benharroch; Tova Lifshitz
Journal:  Int Ophthalmol       Date:  2007-02-17       Impact factor: 2.031

Review 4.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).

Authors:  William Stevenson; Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Reza Dana
Journal:  Ocul Surf       Date:  2012-01-25       Impact factor: 5.033

5.  Femtosecond laser-assisted selective reduction of neovascularization in rat cornea.

Authors:  Mehra S Sidhu; Min-Yeong Choi; Suk-Yi Woo; Hyun-Kyu Lee; Heung-Soon Lee; Kyu-Jin Kim; Sae Chae Jeoung; Jun-Sub Choi; Choun-Ki Joo; Il-Hong Park
Journal:  Lasers Med Sci       Date:  2014-02-26       Impact factor: 3.161

6.  Topical ranibizumab as a treatment of corneal neovascularization.

Authors:  Giulio Ferrari; Mohammad H Dastjerdi; Andre Okanobo; Sheng-Fu Cheng; Francisco Amparo; Nambi Nallasamy; Reza Dana
Journal:  Cornea       Date:  2013-07       Impact factor: 2.651

Review 7.  Corneal transparency: genesis, maintenance and dysfunction.

Authors:  Yureeda Qazi; Gilbert Wong; Bryan Monson; Jack Stringham; Balamurali K Ambati
Journal:  Brain Res Bull       Date:  2009-05-27       Impact factor: 4.077

8.  Photodynamic therapy with verteporfin for corneal neovascularization.

Authors:  Abdullah A Al-Torbak
Journal:  Middle East Afr J Ophthalmol       Date:  2012 Apr-Jun

Review 9.  Therapeutic approaches for corneal neovascularization.

Authors:  Sepehr Feizi; Amir A Azari; Sharareh Safapour
Journal:  Eye Vis (Lond)       Date:  2017-12-10

10.  A CARE-compliant article: ipsilateral progressive idiopathic lipid keratopathy: A case report.

Authors:  Yilin Pang; Qin Zhang; Yongzhen Bao
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.